FCGR1A and inflammatory bowel disease: Future studies will be needed to evaluate the role of CD64 and potentially other Fc receptors in modulating efficacy of anti-TNF drugs in more controlled clinical setting thereby creating a perspective for personalized biological therapy for IBD patients.